Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 92 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

16%

15 trials in Phase 3/4

Results Transparency

21%

7 of 33 completed with results

Key Signals

7 with results100% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (12)
P 1 (1)
P 2 (7)
P 3 (6)
P 4 (9)

Trial Status

Completed33
Recruiting23
Unknown15
Active Not Recruiting9
Not Yet Recruiting5
Enrolling By Invitation4

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (92)

Showing 20 of 20 trials
NCT07735494Not ApplicableRecruitingPrimary

Physical Activity Promotion and Clinical Remission in Severe Asthma

NCT07532265Phase 2RecruitingPrimary

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07721376Active Not RecruitingPrimary

Multi-omics in Severe Asthma From Olive Pollen Allergy

NCT07713498Enrolling By InvitationPrimary

Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

NCT07359846Phase 3RecruitingPrimary

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

NCT07276724Phase 3RecruitingPrimary

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT06705764Phase 4RecruitingPrimary

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)

NCT05018299Phase 2CompletedPrimary

Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

NCT07654842Phase 4Not Yet Recruiting

Fasenra: An Asthma Study

NCT06985225RecruitingPrimary

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

NCT06666504CompletedPrimary

The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Study

NCT07363642Phase 3RecruitingPrimary

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

NCT06472310RecruitingPrimary

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

NCT07655037Not ApplicableRecruitingPrimary

Execise Intervention in Adult Severe Asthma

NCT06473779Phase 3Active Not RecruitingPrimary

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT07218172Active Not RecruitingPrimary

Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)

NCT06998095Not Yet RecruitingPrimary

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

NCT06966479Phase 2Active Not RecruitingPrimary

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06566885Active Not RecruitingPrimary

Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia

NCT04680117Not ApplicableCompletedPrimary

Defining the Severe Paediatric Asthma Endotype

Scroll to load more

Research Network

Activity Timeline